Inhaled human insulin (Exubera®): Clinical profile and patient considerations

Vascular Health and Risk Management

Volumn 3, Issue 1, 2007, Pages 83-91

  Barnett, Anthony H ^a,b   Bellary, Sri ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b BIRMINGHAM HEARTLANDS HOSPITAL   (United Kingdom)

Author keywords

Diabetes; Exubera; Hyperglycemia; Inhaled human insulin

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; HEMOGLOBIN A1C; INSULIN; INSULIN ANTIBODY; INSULIN DERIVATIVE; INSULIN LISPRO; ISOPHANE INSULIN; METFORMIN; ORAL ANTIDIABETIC AGENT; SULFONYLUREA;

CLINICAL PROTOCOL; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; COUGHING; DISEASE SEVERITY; DRUG ABSORPTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; HUMAN; HYPERGLYCEMIA; HYPOGLYCEMIA; INCIDENCE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; LUNG FUNCTION; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT SATISFACTION; REVIEW; SIDE EFFECT; WEIGHT GAIN;

ADMINISTRATION, INHALATION; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPERGLYCEMIA; INSULIN; PATIENT COMPLIANCE; PATIENT SATISFACTION; TREATMENT OUTCOME;

EID: 34249862554     PISSN: 11766344     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (68)

1. American Diabetes Association. 1998. Consensus Development Conference on the diagnosis of coronary heart disease in people with diabetes. 10-11 February 1998, Miami, Florida. Diabetes Care, 21:1551-9.
2. Barnett AH, Dreyer M, Lange P, et al. 2006a. An open, randomized, parallel group study to compare the efficacy and safety profile of inhaled human insulin (Exubera®) with metformin as adjunctive therapy in patients with type 2 diabetes poorly controlled on a sulfonylurea. Diabetes Care, 29:1282-7.
3. Barnett AH, Dreyer M, Lange P, et al. 2006b An open, randomized, parallel-group study to compare the efficacy and safety profile of inhaled human insulin (Exubera) with glibenclamide as adjunctive therapy in patients with type 2 diabetes poorly controlled on metformin. Diabetes Care, 29:1818-25.
4. Becker RHA, Sha S, Frick AD, et al. 2006. The effect of smoking cessation and subsequent resumption on absorption of inhaled insulin. Diabetes Care, 29:277-82.
5. Brown JB, Nichols GA. 2003. Slow response to loss of glycemic control in type 2 diabetes mellitus. Am J Manag Care, 9:213-7.
6. Campbell IW 2000. Need for intensive, early glycaemic control in patients with type 2 diabetes. Br J Cardiol, 7:625-31.
7. Cappelleri JC, Ceralu WT, Rosenstock J, Kourides IA, Gerber RA. 2002. Treatment satisfaction with inhaled insulin in patients with type 2 diabetes: a randomized controlled trial. Clin Ther, 24:552-64.
8. Cefalu WT. 2001. Inhaled insulin: a proof-of-concept study. Ann Intern Med, 134:795-6.
9. Cefalu WT, Skyler JS, Kourides IA, et al. 2001. Inhaled human insulin treatment in patients with type 2 diabetes mellitus. Ann Intern Med, 134:203-7.
10. Ceriello, A, Cavarape A, Martinelli L, et al. 2004. The post-prandial state in type 2 diabetes and endothelial dysfunction: effects of insulin aspart. Diabet Med, 21:171-5.
11. Ciofetta M, Lalli C, Del Sindaco P, et al. 1999. Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime. Diabetes Care, 22:795-800.
12. Cook MN, Girman CJ, Stein PP, et al. 2005. Glycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetes. Diabetes Care, 28:995-1000.
13. DCCT. 1993. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group. N Engl J Med, 329:977-86.
14. DCCT/EDIC. 2002. Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA, 287:2563-9.
15. Del Prato S, Felton A-M, Munro N, et al. 2005. Improving glucose management: ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract, 59:1345-55.
16. Del Sindaco P, Ciofetta M, Lalli C, et al. 1998. Use of the short-acting insulin analogue lispro in intensive treatment of type 1 diabetes mellims: importance of appropriate replacement of basal insulin and time-interval injection-meal. Diabet Med, 15:592-600.
17. Dreyer M, for the Exubera® Phase III Study Group. 2004. Efficacy and two-year pulmonary safety of inhaled insulin as adjunctive therapy with metformin or glibenclamide in type 2 diabetes patients poorly controlled with oral monotherapy [abstract]. Diabetologia, 47(Suppl 1):A44.
18. Dumas R, England RD, Riese RJ, et al. 2005. Exubera® is well tolerated and achieves tight glycemic control in patients with type 1 diabetes [abstract]. Diabetes, 54(Suppl 1):A87.
19. Esposito K, Giugliano D, Nappo F, et al. 2004. Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation, 110:214-9.
20. Fineberg SE, Kawabata T, Finco-Kent D, et al. 2005. Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes. An analysis of initial phase II and III inhaled insulin (Exubera) trials and a two-year extension trial. Endocrinol Metab, 90:3287-94.
21. Freemantle N, Blonde L, Duhot D, et al. 2005. Availability of inhaled insulin promotes greater perceived acceptance of insulin therapy in patients with type 2 diabetes. Diabetes Care, 28:427-8.
22. Funnell MM, Kruger DF, Spencer M. 2004. Self-management support for insulin therapy in type 2 diabetes. Diabetes Educ, 30:274-80.
23. Gerber RA, Cappelleri JC, Kourides IA, Gelfand RA. 2001. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes: a randomized controlled trial. Diabetes Care, 24:1556-9.
24. Goldfine AB, Goldfine HL. 2003. Cardiovascular disease in the diabetic patient. Circulation, 107:e14-16.
25. Gungor N, Arslanian S. 2002. Pathophysiology of type 2 diabetes mellitus in children and adolescents: treatment implications. Treat Endocrinol, 1:359-71.
26. Hauber AB, Johnson FR, Sauriol L, et al. 2005. Risking health to avoid injections: preferences of Canadians with type 2 diabetes. Diabetes Care, 28:2243-5.
27. Hayward RA, Manning WG, Kaplan SH, et al. 1997. Starting insulin therapy in patients with type 2 diabetes: effectiveness, complications, and resource utilization. JAMA, 278:1663-9.
28. Heinemann L. 2004. Overcoming obstacles: new management options. Eur J Endocrinol, 151 (Suppl 2):T23-T7.
29. Henry R, Mudaliar S, Fryburg DA, et al. 2003. Within-subject variability of inhaled insulin (Exubera®) versus subcutaneous regular insulin in elderly obese patients with type 2 diabetes mellitus [abstract]. Diabetes, 52(Suppl 1):A105.
30. Hollander PA, Blonde L, Rowe R, et al. 2004. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 2 diabetes. Diabetes Care, 27:2356-62.
31. Hunt LM, Valenzuela MA, Pugh JA. 1997. NIDDM patients' fears and hopes about insulin therapy: the basis of patient reluctance. Diabetes Care, 20:292-8.
32. 1c with cardiovascular disease and mortality in adults: the European Prospective Investigation into Cancer in Norfolk. Ann Intern Med, 141:413-20.
33. Koro CE, Bowlin SJ, Bourgeois N, et al. 2004. Glycemic control from 1988 to 2000 among US adults diagnosed with type 2 diabetes. Diabetes Care, 27:17-20.
34. Korytkowski M. 2002. When oral agents fail: practical barriers to starting insulin. Int J Obes, 26(Suppl 3):S18-S24.
35. Lazar HL, Chipkin SR, Fitzgerald CA, et al. 2004. Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events. Circulation, 109:1497-502.
36. Leiter LA, Ceriello A, Davidson JA, et al. 2005. Postprandial glucose regulation: new data and new implications. Clin Ther, 27(Suppl B):S42-S56.
37. Liebl A, Mata M, Eschwege E. 2002. Evaluation of risk factors for development of complications in type II diabetes in Europe. Diabetologia, 45:S23-S28.
38. Malmberg K. 1997. Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. Br Med J, 314:1512-5.
39. Malone JK, Beattie SD, Campaigne BN, et al. 2003. Therapy after single oral agent failure: adding a second oral agent or an insulin mixture? Diabetes Res Clin Pract, 62:187-95.
40. Malmberg K, Norhammar A, Wedel H, et al. 1999. Glycometabolic state at admission: important risk marker of mortality in conventionally treated patients with diabetes mellitus and acute myocardial infarction. Long-term results from the Diabetes and Insulin-Glucose Infusion in Acute Myocardial Infarction (DIGAMI) Study. Circulation, 99:2626-32.
41. Mudaliar S, Henry RR. 1999. Combination therapy for type 2 diabetes. Endocr Pract, 5:208-19.
42. Nathan DM. 2002. Clinical practice. Initial management of glycemia in type 2 diabetes mellitus. N Engl J Med, 347:1342-9.
43. Odegard PS, Capoccia KL. 2005. Inhaled insulin: Exubera. Ann Pharmacother, 39:843-53.
44. Patton JS, Bukar JG, Eldon MA. 2004. Clinical pharmacokinetics and pharmacodynamics of inhaled insulin. Clin Pharmacokinet, 43:781-801.
45. Polonsky WH, Fisher L, Guzman S, et al. 2005. Psychological insulin resistance in patients with type 2 diabetes. Diabetes Care, 28:2543-5.
46. Quattrin T, Belanger A, Bohannon NJV et al. 2004. Efficacy and safety of inhaled insulin (Exubera) compared with subcutaneous insulin therapy in patients with type 1 diabetes. Diabetes Care, 27:2622-7.
47. Rave K, Bott S, Heinemann L, et al. 2005. Time-action profile of inhaled insulin in comparison with subcutaneously injected insulin lispro and regular human insulin. Diabetes Care, 28:1077-82.
48. Reichard P, Berglund B, Britz A, et al. 1991. Intensified conventional insulin treatment retards the microvascular complications of insulin-dependent diabetes mellitus (IDDM): the Stockholm Diabetes Intervention Study (SDIS) after 5 years. J Intern Med, 230:101-8.
49. Riddle MC. 2002. The underuse of insulin therapy in North America. Diabetes Metab Res Rev, 18(Suppl 3):S42-S49.
50. Riese RJ, Teeter JG, England RD. 2005. Inhaled insulin does not induce immediate airway responsiveness in patients with type 1 diabetes mellitus [abstract]. Eur Respir J, 26(Suppl 49):582S.
51. Rosenstock J, Cappelleri JC, Bolinder B, Gerber RA. 2004. Patient satisfaction and glycemic control after 1 year with inhaled insulin (Exubera) in patients with type 1 or type 2 diabetes. Diabetes Care, 27:1318-23.
52. Rosenstock J, Zinman B, Murphy LJ, et al. 2005. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes. Ann Intern Med, 143:549-58.
53. Royle P, Waugh N, McAuley L, et al. 2003. Inhaled insulin in diabetes mellitus. Cochrane Database Syst Rev, CD003890.
54. Shichiri M, Kishikawa H, Ohkubo Y, et al. 2000. Long-term results of the Kumamoto Study on Optimal Diabetes Control in type 2 diabetic patients. Diabetes Care, 23(Suppl 2):B21-9.
55. Simonson DC, Hayes JF, Turner RR, et al. 2001. Treatment satisfaction and preferences in type 2 diabetes: a randomized trial of oral agents vs. inhaled insulin [abstract]. Diabetes, 50(Suppl 2):A131.
56. Skyler JS, Cefalu WT, Kourides IA, et al. 2001. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet, 357:331-5.
57. Skyler J, for the Exubera® Phase II Study Group. 2004. Sustained longterm efficacy and safety of inhaled insulin after 4 years of continuous therapy [abstract]. Diabetologia, 47(Suppl 1):A311.
58. Skyler JS, Weinstock RS, Raskin P, et al. 2005. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects. Diabetes Care, 28:1630-5.
59. Stratton IM, Adler AI, Neil HAW, et al. 2000. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. Br Med J, 321:405-12.
60. Testa MA. 2003. Improving diabetes therapy: improving satisfaction. Diabetes Voice, 48:23-5.
61. Turner RC, Cull CA, Frighi V et al. 1999. Glycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49). JAMA, 281:2005-12.
62. UKPDS Group. 1996. UK Prospective Diabetes Study 17: A nine-year update of a randomized, controlled trial on the effect of improved metabolic control on complications in non-insidin-dependent diabetes mellitus. Ann Intern Med, 124:136-45.
63. UKPDS Group. 1998. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet, 352:837-53.
64. Van den Berghe G, Wouters P, Weekers F, et al. 2001. Intensive insulin therapy in critically ill patients. N Engl J Med, 345:1359-67.
65. Weiss SR, Cheng S-L, Kourides IA, et al. 2003. Inhaled insulin provides improved glycemic control in patients with type 2 diabetes mellitus inadequately controlled with oral agents. Arch Intern Med, 163:2277-82.
66. [WHO] World Health Organization (online]. Accessed 28 February 2006. URL: http://www.who.int/diabetes/facts/world_figures/en.
67. Wright A, Burden ACF, Paisey RB, et al, for the UK Prospective Diabetes Study Group. 2002. Sulfonylurea inadequacy: efficacy of addition of insulin over 6 years in patients with type 2 diabetes in the UK Prospective Diabetes Study (UKPDS 57). Diabetes Care, 25:330-6.
68. Zambanini A, Newson RB, Maisey M, et al. 1999. Injection related anxiety in insulin-treated diabetes. Diab Res Clin Pract, 46:239-46.